On the other hand, cisplatin can trigger RIPK3-mediated necroptosis in tumor cells, leading to the release of cytosolic mtDNA, initiation of the cGAS–STING pathway, and secretion of IFN-I, consequently promoting the cross-activation of T cells through APCs. The gene discussed is RIPK3; the disease is neoplasm.